In vitro screening of major neurotransmitter systems possibly involved in the mechanism of action of antibodies to S100 protein in released- active form

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 2837-2846

  Gorbunov, Evgeniy A ^a   Ertuzun, Irina A ^a   Kachaeva, Evgeniya V ^a   Tarasov, Sergey A ^a   Epstein, Oleg I ^a  

^a OOO NPF MATERIA MEDICA HOLDING   (Russian Federation)

Author keywords

Dopamine agent; Released activity; Serotonin agent; Sigma1 receptor

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; DOPAMINE RECEPTOR; PROTEIN ANTIBODY; PSYCHOTROPIC AGENT; S 100 ANTIBODY; SEROTONIN RECEPTOR; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; EC50; IC50; IN VITRO STUDY; INHIBITION CONSTANT; NONHUMAN; PROTEIN DETERMINATION;

EID: 84946593852     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S92456     Document Type: Article

References (59)

1. Epstein OI. Release-activity: a long way from phenomenon to new drugs. Bull Exp Biol Med. 2012;154(1):54-58.
2. Epstein OI. [The phenomenon of release activity and the hypothesis of “spatial” homeostasis]. Usp Fiziol Nauk. 2013; 44(3):54-76. Russian.
3. Nicoll J, Gorbunov EA, Tarasov SA, Epstein OI. Subetta treatment increases adiponectin secretion by mature human adipocytes in vitro. Int J Endocrinol. 2013;2013:925874.
4. Bailbé D, Philippe E, Gorbunov E, Tarasov S, Epstein O, Portha B. The novel oral drug Subetta exerts an antidiabetic effect in the diabetic Goto-Kakizaki rat: comparison with rosiglitazone. J Diabetes Res. 2013;2013:763125.
5. Sakat SS, Mani K, Demidchenko YO, et al. Release-active dilutions of diclofenac enhance anti-inflammatory effect of diclofenac in carrageenan-induced rat paw edema model. Inflammation. 2014; 37(1):1-9.
6. Sizova LV. Treatment of early arthritis using arthrofoon (ultra-low doses of antibodies to tumor necrosis factor-α). Indian J Pharmacol. 2011;43(6):724-725.
7. Tarasov SA, Zarubaev VV, Gorbunov EA, Sergeeva SA, Epstein OI. Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice. Antiviral Res. 2012;93(2):219-224.
8. Chu X, Agmo A. Sexual incentive motivation in old male rats: the effects of sildenafil and a compound (Impaza) stimulating endothelial NO synthase. Pharmacol Biochem Behav. 2008;89(2):209-217.
9. Dugina JL, Petrov VI, Babayeva AR, et al. A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis. Int J Tissue React. 2005;27(1):15-21.
10. Epstein OI. Ultra-Low Doses (History of One Study). Moscow: Publishing House of RAMN; 2009.
11. Karpova GV, Fomina TI, Vetoshkina TV, et al. Preclinical studied of general toxic properties of preparations containing ultralow doses of antibodies to endogenous regulators. Bull Exp Biol Med. 2009;148(3):543-546.
12. Epshteĭn OI, Beregovoĭ NA, Sorokina NS, Starostina MV, Shtark MB. [Effect of various dilutions of the potentiated antibodies to the brain-specific protein S-100 on the post-titanic potentiation in surviving hippocampal slices]. Biull Eksp Biol Med. 1999;127(3):317-320. Russian.
13. Kubista H, Donato R, Hermann A. S100 calcium binding protein affects neuronal electrical discharge activity by modulation of potassium currents. Neuroscience. 1999;90(2):493-508.
14. Epshteĭn OI, Gaĭnutdinov KL, Shtark MB. [Effect of homeopathic doses of antibodies to antigen S-100 on the electric parameters of neuronal membranes]. Biull Eksp Biol Med. 1999;127(4):466-467. Russian.
15. Epshtein OI, Gainutdinov KL, Shtark MB. Effect of homeopathic doses of antibodies to antigen S-100 on the electric parameters of neuronal membranes. Bull Exp Biol Med. 2003;127:111-113.
16. Andrianov VV, Epstein OI, Gainutdinova TKH, Shtark MB, Timoshenko AKH, Gainutdinov KL. Antibodies to calcium-binding S100B protein block the conditioning of long-term sensitization in the terrestrial snail. Pharmacol Biochem Behav. 2009;94(1):37-42.
17. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003;60(6):540-551.
18. Donato R, Cannon BR, Sorci G, et al. Functions of S100 proteins. Curr Mol Med. 2013;13(1):24-57.
19. Hermann A, Donato R, Weiger TM, Chazin WJ. S100 calcium binding proteins and ion channels. Front Pharmacol. 2012;3:67.
20. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J. 2006;396(2):201-214.
21. Kheifets IA, Dugina YL, Voronina TA, et al. Involvement of the serotoninergic system in the mechanism of action of ultralow dose antibodies to S-100 protein. Bull Exp Biol Med. 2007;143(5):598-600.
22. Voronina TA, Molodavkin GM, Sergeeva SA, Epstein OI. GABAergic system in the anxiolytic effect of proproten: experimental study. Bull Exp Biol Med. 2003;135(suppl 7):125-127.
23. Kheifez IA, Molodavkin GM, Voronina TA, Dugina YL, Sergeeva SA, Epstein OI. Involvement of the GABA-B system in the mechanism of action of ultralow-dose antibodies to S-100 protein. Bull Exp Biol Med. 2008;145(5):614-616.
24. Ito H, Kiso T, Miyata K, et al. Pharmacological profile of YM-31636, a novel 5-HT3 receptor agonist, in vitro. Eur J Pharmacol. 2000;409(2): 195-201.
25. Mikami T, Komada T, Sugimoto H, et al. In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT(4) receptor. Eur J Pharmacol. 2009;609(1-3): 5-12.
26. Zhang Y, Gilliam A, Maitra R, et al. Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor. J Med Chem. 2010;53(19):7048-7060.
27. Sittampalam G, Coussens N, Nelson H, et al. Assay Guidance Manual. Bethesda, MD: Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004. Available from: http://www. ncbi.nlm.nih.gov/books/NBK53196/. Accessed May 4th, 2012.
28. Epstein OI, Shtark MB, Kolyadko TM, inventors; Oleg I. Epshtein, assignee. Method of treating a pathological syndrome and a pharma- ceutical agent. United States patent US 8535664. 2013 Sep 17.
29. Hayesa DJ, Greenshawa AJ. 5-HT receptors and reward-related behavior: a review. Neurosci Biobehav Rev. 2011;35(6):1419-1449.
30. Im WB, Chio CL, Alberts GL, Dinh DM. Positive allosteric modulator of the human 5-HT2C receptor. Mol Pharmacol. 2003;64(1):78-84.
31. de Oliveira-Pierce AN, Zhang R, Machu TK. Colchicine: a novel positive allosteric modulator of the human 5-hydroxytryptamine3A receptor. J Pharmacol Exp Ther. 2009;329(2):838-847.
32. Castagne V, Lemaire M, Kheyfets I, Dugina JL, Sergeeva SA, Epstein OI. Antibodies to S100 proteins have anxiolytic-like activity at ultra-low doses in the adult rat. J Pharm Pharmacol. 2008;60(3):309-316.
33. Loskutova LV, Shtark MB, Epstein OI. Efficiency of ultralow doses of antibodies to S100 protein and delta sleep-inducing peptide in rats with anxious depression. Bull Exp Biol Med. 2003;135(suppl 7):20-22.
34. Banerjee P, Mehta M, Kanjilal B. The 5-HT1A receptor: a signaling hub linked to emotional balance. In: Chattopadhyay A, editor. Serotonin Receptors in Neurobiology. (Chap. 7). Boca Raton, FL: CRC Press; 2007. Available from: http://www.ncbi.nlm.nih.gov/books/NBK5212/
35. Moret C, Briley M. The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol. 2000;404(1-2):1-12.
36. Hudzik TJ, Yanek M, Porrey T, et al. Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist. J Pharmacol Exp Ther. 2003;304(3):1072-1084.
37. Diaz SL, Doly S, Narboux-Nême N, et al. 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol Psychiatry. 2012;17(2):154-163.
38. Kennett GA, Trail B, Bright F. Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated. Neuropharmacology. 1998;37(12):1603-1610.
39. Graeff FG. Serotonin, the periaqueductal gray and panic. Neurosci Biobehav Rev. 2004;28(3):239-259.
40. Bristow LJ, O’Connor D, Watts R, Duxon MS, Hutson PH. Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100,635, in the rat. Neuropharmacology. 2000;39(7): 1222-1236.
41. Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol. 2001;4(4):399-408.
42. Mongeau R, Martin CB, Chevarin C, et al. 5-HT2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extra-cellular levels in the mouse brain: modulation by chronic paroxetine treatment. J Neurochem. 2010;115(2):438-449.
43. Varani AP, Balerio GN. GABA(B) receptors involvement in the effects induced by nicotine on anxiety-related behaviour in mice. Pharmacol Res. 2012;65(5):507-513.
44. Nowak G, Partyka A, Pałucha A, et al. Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br J Pharmacol. 2006;149(5):581-590.
45. Lasarge CL, Bañuelos C, Mayse JD, Bizon JL. Blockade of GABA(B) receptors completely reverses age-related learning impairment. Neuroscience. 2009;164(3):941-947.
46. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today. 2005;10(13):917-925.
47. Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Functional potencies of dopamine agonists and antagonists at human dopamine D2 and D3 receptors. Eur J Pharmacol. 2011;666(1-3):43-52.
48. Matsumoto RR, Bowen WD, Su T-P. Sigma Receptors, Chemistry, Cell Biology and Clinical Implication. Springer Science + Business Media, LLC: New York (NY), USA; 2007.
49. Andrianov V V, Gainutdinov, K H L, Gainutdinova, T K H, Mukhamedshina, DI, Shtark MB. Membranotropic effects of antibodies to S100 protein in ultralow doses. Bull Exp Biol Med. 2003;1:114-116.
50. Drücker P, Pejic M, Galla HJ, Gerke V. Lipid segregation and membrane budding induced by the peripheral membrane binding protein annexin A2. J Biol Chem. 2013;288(34):24764-24776.
51. Roux BT, Cottrell GS. G protein-coupled receptors: what a difference a ‘partner’ makes. Int J Mol Sci. 2014;15(1):1112-1142.
52. Chichili GR, Rodgers W. Cytoskeleton-membrane interactions in membrane raft structure. Cell Mol Life Sci. 2009;66(14):2319-2328.
53. Björk K, Svenningsson P. Modulation of monoamine receptors by adaptor proteins and lipid rafts: role in some effects of centrally acting drugs and therapeutic agents. Annu Rev Pharmacol Toxicol. 2011;51: 211-242.
54. Fantini J, Barrantes FJ. Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim Biophys Acta. 2009;1788(11):2345-2361.
55. Preininger AM, Meiler J, Hamm HE. Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: a perspective. J Mol Biol. 2013;425(13):2288-2298.
56. Padgett CL, Slesinger PA. GABAB receptor coupling to G-proteins and ion channels. Adv Pharmacol. 2010;58:123-147.
57. Li J, Liu B, Gao X, et al. Overexpression of sigma-1 receptor inhibits ADAM10 and ADAM17 mediated shedding in vitro. Protein Cell. 2012;3(2):153-159.
58. Egeland M, Warner-Schmidt J, Greengard P, Svenningsson P. Co-expression of serotonin 5-HT(1B) and 5-HT(4) receptors in p11 containing cells in cerebral cortex, hippocampus, caudate-putamen and cerebellum. Neuropharmacology. 2011;61(3):442-450.
59. Liu Y, Buck DC, Neve KA. Novel interaction of the dopamine D2 receptor and the Ca2+ binding protein S100B: role in D2 receptor function. Mol Pharmacol. 2008;74(2):371-378.